In Brief: Pfizer cetirizine

Pfizer cetirizine: "Approvable" as of Feb. 21 for seasonal allergic rhinitis, perennial allergic rhinitis and chronic urticaria. Pfizer's oral antihistamine (NDA 19-835) was recommended for approval for those indications at an April 1993 FDA Pulmonary-Allergy Drugs Advisory Committee meeting. The drug is marketed elsewhere as Zyrtec; Pfizer has referred to the therapy as Reactine, but the final product name is still under discussion with FDA and should be determined within the next two months, Pfizer says. Pfizer has a trademark, Certex-24, in registration with the PTO for an anti-allergy product...